SCHEMBL9996019

SCHEMBL9996019

Cc1cc(=O)oc2cc3c([N+](=O)[O-])c(O)ccc3cc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 2/20 1.00
PIM1 P11309 1/20 1.00
PIM3 Q86V86 1/20 1.00
PIM2 Q9P1W9 1/20 1.00
MCL1 Q07820 6/20 0.62
KDM4E B2RXH2 6/20 0.52
ALDH1A1 P00352 6/20 0.52
HSD17B10 Q99714 4/20 0.52
HPGD P15428 3/20 0.52
AKR1B1 P15121 2/20 0.52
CYP3A4 P08684 2/20 0.52
THRB P10828 2/20 0.52
ALB P02768 1/20 0.47
GAA P10253 5/20 0.47
MAOB P27338 3/20 0.47
LMNA P02545 3/20 0.47
CYP1A2 P05177 2/20 0.47
CASP1 P29466 2/20 0.47
CASP7 P55210 2/20 0.47
GLA P06280 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4929327 0.78 PIM1 (0.64) DYRK1APIM1PIM3PIM2MCL1
SCHEMBL981095 0.77 MCL1 (1.00) DYRK1APIM1PIM3PIM2MCL1
SCHEMBL26933655 0.71 PIM1 (0.55) DYRK1APIM1PIM3PIM2MCL1
SCHEMBL10719531 0.71 CYP3A4 (0.59) DYRK1APIM1PIM3PIM2MCL1
SCHEMBL30435464 0.71 DYRK1A (1.00) DYRK1APIM1PIM3PIM2MCL1
SCHEMBL29019847 0.71 DYRK1A (1.00) DYRK1APIM1PIM3PIM2MCL1
4-Methylesculetin SCHEMBL409482 0.70 MCL1 (1.00) DYRK1AMCL1KDM4EALDH1A1HSD17B10
4-Methylesculetin SCHEMBL29361762 0.70 MCL1 (1.00) DYRK1AMCL1KDM4EALDH1A1HSD17B10
SCHEMBL26933730 0.70 ESR1 (0.63) DYRK1APIM1PIM3PIM2MCL1
SCHEMBL24865598 0.69 ALDH1A1 (0.82) DYRK1APIM1PIM3PIM2MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110305706-A1 Compositions and Methods for Treating a Disease Mediated by Soluble Oligomeric Amyloid Beta THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS 2011-12-15 US disclosed